Abstract:B cell follicles are specialized microenvironments that support events necessary for humoral immunity 1, 2, 3. Following antigen encounter, activated B cells initially seek T cell help at the follicle-T zone boundary and then move to interfollicular and T-zone distal (outer) regions of the follicle 4, 5, 6, 7, 8, 9, 10. Subsequently, some cells move to the follicle center, become germinal center (GC) B cells and undergo antibody affinity maturation 1, 2, 11. Although germinal ‘centers’ within follicles were de… Show more
“…2G). The bias toward GC differentiation in self-reactive B cells may result from decreased BCR signaling to NF-κB and consequent poor induction of Ebi2 and Irf4 in anergic B cells (37), because induction of these genes favors plasma cell differentiation and disfavors GC differentiation (38)(39)(40).…”
The best-understood mechanisms for achieving antibody self/nonself discrimination discard self-reactive antibodies before they can be tested for binding microbial antigens, potentially creating holes in the repertoire. Here we provide evidence for a complementary mechanism: retaining autoantibodies in the repertoire displayed as low levels of IgM and high IgD on anergic B cells, masking a varying proportion of autoantibody-binding sites with carbohydrates, and removing their self-reactivity by somatic hypermutation and selection in germinal centers (GCs). Analysis of human antibody sequences by deep sequencing of isotype-switched memory B cells or in IgG antibodies elicited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of anergic IgM low IgD+ IGHV4-34+ B cells and removal of cold agglutinin self-reactivity by hypermutation, often accompanied by mutations that inactivated an N-linked glycosylation sequon in complementarity-determining region 2 (CDR2). In a Hy10 antibody transgenic model where anergic B cells respond to a biophysically defined lysozyme epitope displayed on both foreign and self-antigens, cell transfers revealed that anergic IgM low IgD+ B cells form twice as many GC progeny as naïve IgM hi IgD+ counterparts. Their GC progeny were rapidly selected for CDR2 mutations that blocked 72% of antigen-binding sites with N-linked glycan, decreased affinity 100-fold, and then cleared the binding sites of blocking glycan. These results provide evidence for a mechanism to acquire self/non-self discrimination by somatic mutation away from self-reactivity, and reveal how varying the efficiency of N-glycosylation provides a mechanism to modulate antibody avidity.self-tolerance | affinity maturation | clonal selection | autoimmunity
“…2G). The bias toward GC differentiation in self-reactive B cells may result from decreased BCR signaling to NF-κB and consequent poor induction of Ebi2 and Irf4 in anergic B cells (37), because induction of these genes favors plasma cell differentiation and disfavors GC differentiation (38)(39)(40).…”
The best-understood mechanisms for achieving antibody self/nonself discrimination discard self-reactive antibodies before they can be tested for binding microbial antigens, potentially creating holes in the repertoire. Here we provide evidence for a complementary mechanism: retaining autoantibodies in the repertoire displayed as low levels of IgM and high IgD on anergic B cells, masking a varying proportion of autoantibody-binding sites with carbohydrates, and removing their self-reactivity by somatic hypermutation and selection in germinal centers (GCs). Analysis of human antibody sequences by deep sequencing of isotype-switched memory B cells or in IgG antibodies elicited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of anergic IgM low IgD+ IGHV4-34+ B cells and removal of cold agglutinin self-reactivity by hypermutation, often accompanied by mutations that inactivated an N-linked glycosylation sequon in complementarity-determining region 2 (CDR2). In a Hy10 antibody transgenic model where anergic B cells respond to a biophysically defined lysozyme epitope displayed on both foreign and self-antigens, cell transfers revealed that anergic IgM low IgD+ B cells form twice as many GC progeny as naïve IgM hi IgD+ counterparts. Their GC progeny were rapidly selected for CDR2 mutations that blocked 72% of antigen-binding sites with N-linked glycan, decreased affinity 100-fold, and then cleared the binding sites of blocking glycan. These results provide evidence for a mechanism to acquire self/non-self discrimination by somatic mutation away from self-reactivity, and reveal how varying the efficiency of N-glycosylation provides a mechanism to modulate antibody avidity.self-tolerance | affinity maturation | clonal selection | autoimmunity
“…EBI2 is a chemoattractant receptor of the GPCR family with no known roles other than controlling cell migration and/or positioning. Specifically, EBI2 promotes the positioning of dendritic cells and activated B lymphocytes to specialized outer and interfollicular niches in secondary lymphoid organs and plays important roles in primary antibody responses (Gatto et al, 2009(Gatto et al, , 2013Pereira et al, 2009bPereira et al, , 2010aYi et al, 2012;Yi and Cyster, 2013). Thus, the phenotypic similarity between EBI2-and CH25H-deficient mice favor a model in which oxysterols sensed by EBI2 expressed in OCPs regulate bone mass homeostasis predominantly by promoting OCP cell movement and positioning, which facilitates cell fusion and enhances the development of large OCs.…”
Section: Ebi2 Signaling Controls Ocp-directed Migration Toward Bone Smentioning
confidence: 99%
“…However, systemic RANKL administration has been shown to increase OCP homing back to BM and to promote local OC differentiation (Kotani et al, 2013). These studies suggest that OCP movement in and out of BM tissue is highly regulated and that balanced responsiveness to B lymphocyte migration in secondary lymphoid organs (Gatto et al, 2009(Gatto et al, , 2013Pereira et al, 2009b;Hannedouche et al, 2011;Kelly et al, 2011;Liu et al, 2011;Yi and Cyster, 2013), in controlling monocyte and OCP movement and positioning within BM. We show that EBI2 is highly expressed in OCPs and mature OCs and promotes OCP motility in vitro and in various chemoattractants regulates OCP movement and differentiation.…”
mentioning
confidence: 94%
“…C57BL/6 mice were obtained from The Jackson Laboratory. The generation of Ebi2 GFP/GFP mice was described previously (Pereira et al, 2009b Kikuta et al, 2013). TRA-P Red mice were intercrossed with Ebi2 GFP/GFP and with Ch25h / mice to generate TRAP Red Ebi2 GFP/GFP and TRAP Red Ch25h / and littermate control mice.…”
Section: Methodsmentioning
confidence: 99%
“…EBI2 and its oxysterol ligands control immune cell migration (Gatto et al, 2009;Pereira et al, 2009bPereira et al, , 2010aHannedouche et al, 2011;Liu et al, 2011). We hypothesized that EBI2 promotes BMDM and OCP migration, thereby influencing cell-cell interaction and cell fusion.…”
Bone surfaces attract hematopoietic and nonhematopoietic cells, such as osteoclasts (OCs) and osteoblasts (OBs), and are targeted by bone metastatic cancers. However, the mechanisms guiding cells toward bone surfaces are essentially unknown. Here, we show that the Gi protein-coupled receptor (GPCR) EBI2 is expressed in mouse monocyte/OC precursors (OCPs) and its oxysterol ligand 7,25-dihydroxycholesterol (7,25-OHC) is secreted abundantly by OBs. Using in vitro time-lapse microscopy and intravital two-photon microscopy, we show that EBI2 enhances the development of large OCs by promoting OCP motility, thus facilitating cell-cell interactions and fusion in vitro and in vivo. EBI2 is also necessary and sufficient for guiding OCPs toward bone surfaces. Interestingly, OCPs also secrete 7,25-OHC, which promotes autocrine EBI2 signaling and reduces OCP migration toward bone surfaces in vivo. Defective EBI2 signaling led to increased bone mass in male mice and protected female mice from age-and estrogen deficiency-induced osteoporosis. This study identifies a novel pathway involved in OCP homing to the bone surface that may have significant therapeutic potential.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.